Celecoxib exposures reported to Texas poison control centers from 1999 to 2004

Human and Experimental Toxicology

Volumn 25, Issue 5, 2006, Pages 261-266

  Forrester, Mathias B ^a  

^a TEXAS DEPARTMENT OF STATE HEALTH SERVICES   (United States)

Author keywords

Adverse exposures; Celecoxib; Poison control centers

Indexed keywords

CELECOXIB;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGITATION; ARTICLE; ATAXIA; BRONCHOSPASM; BURN; CHILD; COMA; CONFUSION; CONTROLLED STUDY; COUGHING; DILUTION; DIZZINESS; DROWSINESS; DRUG EXPOSURE; DRUG SAFETY; DYSPNEA; EDEMA; FASCICULATION; FEMALE; HEADACHE; HEALTH CARE FACILITY; HUMAN; HYPERTENSION; HYPOTHERMIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN; PARESTHESIA; POISON CENTER; PRIORITY JOURNAL; PRURITUS; RASH; RESPIRATION DEPRESSION; SIDE EFFECT; SLURRED SPEECH; THORAX PAIN; THROAT IRRITATION; TREMOR; URTICARIA; VOMITING;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; CHILD, PRESCHOOL; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HUMANS; MALE; POISON CONTROL CENTERS; POISONING; PYRAZOLES; SULFONAMIDES; TEXAS;

EID: 33744817908     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/0960327106ht625oa     Document Type: Article

References (11)

1. Konstantinopoulos PA, Lehmann DF. The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding. J Clin Pharmacol 2005; 45: 742-50.
2. McEboy GK ed. AHFS drug information 2000. American Society of Health-System Pharmacists, 2000.
3. Moore RA, Derry S, Makinson GT, McQuay HJ. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther 2005; 7: R644-65.
4. Layton D, Wilton LV, Shakir SA. Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study. Eur J Clin Pharmacol 2004; 60: 489-501.
5. Goldenberg MM. Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. Clin Therapeut 1999; 21: 1497-513.
6. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al.; Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New Engl J Med 2005; 352: 1071-80.
7. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. J Am Med Assoc 2000; 284: 1247-55.
8. Forrester MB. Valdecoxib exposures reported to Texas poison centers during 2002-2004. J Toxicol Environ Health A, in press.
9. Watson WA, Litovitz TL, Rodgers GC, Klein-Schwartz W, Reid N, Youniss J, et al. 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2005; 23: 589-666.
10. Monaghan J, Pickford M. Cox-2 inhibitors: a review of toxicity. J Toxicol - Clin Toxicol 2003; 41: 503.
11. Seifert SA, Jacobitz K, Ling L, Bangh S, Bronstein AC, Lansinger PA. Valdecoxib (Bextra®) overdose: a case series. J Toxicol - Clin Toxicol 2004; 42: 723.